300+ investors in your industry, stage, and region Get
Any industry
Artificial Intelligence
Google
EdTech
Clean Energy
Retail
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Organic Food
Email
Fitness
CleanTech
Energy
Health Care
Machine Learning
Agriculture (AgTech)
Marketplace
Gaming
Facebook
Blockchain
B2B
Social Network
Big Data
Video Games
Education
Wellness
Medical Device
Mobile
Construction
Automotive
Legal
Sports
eSports
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Theatre
Recruiting
Crowdfunding
Web3
Medical
Fashion
Social
Venture Capital
Infrastructure
Beauty
Celebrity
Cannabis
Climate
LGBT
Publishing
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Music
Real Estate
Art
Sporting Goods
Digital Media
Finance
Manufacturing
FinTech
Social Media
Financial Services
Franchise
Non Profit
Mobile Advertising
Internet
Android
Biotech
Proptech
Sustainability
Hardware
Transportation
Impact
Enterprise
Community
Media (Entertainment)
Any country
Burkina Faso
South Korea
Africa
LATAM
Singapore
Brazil
Saudi Arabia
Oceania
Greece
Gibraltar
Norway
Liberia
Mexico
Taiwan
Sweden
Zambia
Puerto Rico
Tunisia
Russian Federation
Togo
Tajikistan
Zimbabwe
Nigeria
Guinea
Nepal
Iran
Kyrgyzstan
Isle of Man
Pakistan
Romania
Oman
New Zealand
Cameroon
Colombia
Australia
China
Sri Lanka
Armenia
Costa Rica
Switzerland
Czech Republic
Kenya
Cayman Islands
Kuwait
Kazakhstan
Jamaica
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uganda
Turkey
Uzbekistan
Venezuela
Guatemala
Japan
Malawi
Moldova
Seychelles
Botswana
United Kingdom
Canada
Ireland
South Africa
Egypt
France
Georgia
Denmark
Croatia
Hong Kong
Ghana
Iraq
Mali
Morocco
Myanmar
Latvia
Malaysia
Poland
Philippines
Portugal
Sierra Leone
Rwanda
El Salvador
Senegal
Thailand
Uruguay
Tanzania
India
Germany
United States
Middle East
Indonesia
Bermuda
Dominican Republic
Asia
Albania
Cyprus
Qatar
United Arab Emirates
Spain
Europe
Angola
Argentina
Bangladesh
Barbados
Belgium
Ethiopia
Jordan
Austria
Azerbaijan
Ecuador
Bulgaria
Bahrain
Bahamas
Faroe Islands
Jersey
Estonia
Bolivia
Algeria
Belize
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Cambodia
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology VC Funds & Investors in United States (July 2026)

The most active venture capital funds investing in United States Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in United States Biotechnology startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
ARCH Venture Partners
VC Fund
135 United States, China, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $8.4M–$250M
SOSV
VC Fund
124 United States, India, United Kingdom Seed, Convertible Note, Pre-Seed Biotechnology, Health Care, Software
Alexandria Venture Investments
VC Fund
107 United States, Canada, France Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2M–$150M
OrbiMed
VC Fund
88 United States, China, Israel Series B, Series A, Series C Biotechnology, Health Care, Medical $10M–$151M
Atlas Venture
VC Fund
78 United States, United Kingdom, Canada Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $3.5M–$115M
New Enterprise Associates
VC Fund
71 United States, India, United Kingdom Series A, Series B, Series C Software, Health Care, Biotechnology $5.4M–$103M
Versant Ventures
VC Fund
70 United States, Switzerland, Canada Series A, Series B, Series C Biotechnology, Health Care, Medical $4.7M–$108M
Alumni Ventures
VC Fund
69 United States, United Kingdom, Canada Seed, Series A, Series B Software, Artificial Intelligence, Information Technology $1.5M–$79M
Third Rock Ventures
VC Fund
67 United States Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $11M–$190M
Khosla Ventures
VC Fund
64 United States, India, United Kingdom Series A, Series B, Seed Software, Artificial Intelligence, Health Care $2M–$100M
Polaris Partners
VC Fund
64 United States, Ireland, Singapore Series B, Series A, Series C Biotechnology, Health Care, Medical $4.5M–$107M
RA Capital Management
VC Fund
64 United States, United Kingdom, Canada Series B, Series C, Post-IPO Equity Biotechnology, Health Care, Therapeutics $26M–$240M
5AM Ventures
VC Fund
64 United States, Switzerland, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $13M–$120M
Innova Memphis
VC Fund
63 United States, Argentina, United Kingdom Seed, Pre-Seed Health Care, Medical, Medical Device $25k–$1.7M
MPM Capital
VC Fund
61 United States, Canada, United Kingdom Series B, Series A, Series C Biotechnology, Health Care, Pharmaceutical $9M–$125M
F-Prime
VC Fund
60 United States, United Kingdom, China Series A, Series B, Series C Health Care, Biotechnology, Medical $9.2M–$165M
Gaingels
VC Fund
59 United States, Canada, Mexico Seed, Series A, Series B Software, Health Care, Artificial Intelligence $1.1M–$100M
Google Ventures
VC Fund
58 United States, United Kingdom, Israel Series A, Series B, Seed Software, Health Care, Biotechnology $1.1M–$121M
Canaan Partners
VC Fund
52 United States, United Kingdom, Israel Series A, Series B, Series C Software, Biotechnology, Health Care $5M–$75M
Andreessen Horowitz
VC Fund
51 United States, United Kingdom, Brazil Series A, Seed, Series B Software, Information Technology, Artificial Intelligence $1.6M–$112M
BioAdvance
VC Fund
48 United States, Canada Seed, Series A Biotechnology, Health Care, Medical $350k–$40M
The Column Group
VC Fund
46 United States Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $9.2M–$115M
KdT Ventures
VC Fund
46 United States, India, Canada Seed, Series A, Series B Biotechnology, Health Care, Medical $2.6M–$175M
Connecticut Innovations
VC Fund
45 United States, Israel, Canada Seed, Series A Health Care, Biotechnology, Software $300k–$25M
Lux Capital
VC Fund
45 United States, United Kingdom, Canada Series A, Seed, Series B Software, Artificial Intelligence, Health Care $1.8M–$193M
Novartis Venture Fund
VC Fund
43 United States, Switzerland, United Kingdom Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $5.1M–$120M
Mission BioCapital
VC Fund
43 United States, Switzerland, France Series A, Series B Biotechnology, Health Care, Therapeutics $4.2M–$112M
DCVC
VC Fund
41 United States, Canada, United Kingdom Seed, Series A, Series B Software, Artificial Intelligence, Machine Learning $1.5M–$130M
Fifty Years
VC Fund
41 United States, Germany, Canada Seed, Series A, Series B Biotechnology, Health Care, Artificial Intelligence $2M–$91M
Novo Holdings
VC Fund
40 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9M–$135M
Dolby Family Ventures
VC Fund
40 United States, Austria, Germany Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $2M–$75M
Pfizer Venture Investments
VC Fund
39 United States, United Kingdom, Switzerland Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $10M–$123M
Hatteras Venture Partners
VC Fund
39 United States, Canada Series A, Series B, Series C Health Care, Biotechnology, Medical $5M–$90M
Sofinnova Investments
VC Fund
38 United States, France, Switzerland Series B, Series A, Series C Biotechnology, Health Care, Pharmaceutical $7.3M–$150M
Frazier Healthcare Partners
VC Fund
38 United States, Canada, Ireland Series B, Series A, Post-IPO Equity Biotechnology, Health Care, Therapeutics $10M–$235M
Northpond Ventures
VC Fund
38 United States, United Kingdom, Canada Series A, Series B, Series C Biotechnology, Health Care, Life Science $10M–$100M
Civilization Ventures
VC Fund
37 United States, United Kingdom, Brazil Seed, Series A, Series B Biotechnology, Health Care, Medical $1.7M–$144M
Boston Harbor Angels
VC Fund
36 United States, Canada, India Angel, Seed, Series A Biotechnology, Health Care, Medical Device $100k–$6M
Apple Tree Partners
VC Fund
36 United States, Canada, United Kingdom Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $3.8M–$90M
Omega Funds
VC Fund
36 United States, Switzerland, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $14M–$208M
Refactor
VC Fund
36 United States, United Kingdom, New Zealand Seed, Series A, Series B Health Care, Biotechnology, Medical $2.7M–$103M
Illumina Ventures
VC Fund
35 United States, United Kingdom, France Series A, Series B, Series C Biotechnology, Health Care, Medical $8M–$220M
Life Science Angels
VC Fund
35 United States, Israel, The Netherlands Seed, Series A Biotechnology, Health Care, Medical $1M–$20M
Founders Fund
VC Fund
35 United States, United Kingdom, Germany Series A, Seed, Series B Software, Health Care, Information Technology $1.5M–$100M
General Catalyst
VC Fund
34 United States, United Kingdom, India Series A, Seed, Series B Software, Artificial Intelligence, Health Care $1.8M–$130M
Amgen Ventures
VC Fund
34 United States, Canada, United Kingdom Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $4.4M–$110M
Flagship Pioneering
VC Fund
34 United States, Canada, United Kingdom Series B, Series C, Series A Biotechnology, Health Care, Medical $5.5M–$140M
Digitalis Ventures
VC Fund
33 United States, United Kingdom, China Series A, Series B, Seed Biotechnology, Health Care, Medical $1.5M–$132M
Domain Associates
VC Fund
33 United States, Canada, Estonia Series B, Series C, Series A Biotechnology, Health Care, Medical $3.8M–$60M
8VC
VC Fund
32 United States, United Kingdom, Canada Series A, Seed, Series B Software, Health Care, Artificial Intelligence $2.5M–$175M
Access all 7871 VC funds in United States Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

ARCH Venture Partners
VC Fund · Chicago, Illinois, United States · 135 investments in United States Biotechnology startups

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, China, United Kingdom

Investor stats

  • Total investments: 414
  • Round size: Series A $8.4M–$213M; Series B $14M–$250M; Series C $15M–$175M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Synchron — The endovascular brain computer interface.
  • Parabilis Medicines — Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
  • HI-Bio — HI-Bio leverages human genetic and immunological insights to deliver targeted, effective medicines to patients with immune-mediated diseases.
Show all investments...

SOSV
VC Fund · Princeton, New Jersey, United States · 124 investments in United States Biotechnology startups, 75 in the past 12 months

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note, Pre-Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1482
  • Lead/follow: no public data

Portfolio highlights

  • MixRift — MIXRIFT - game developers specialized in Mixed Reality
  • unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
  • Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Show all investments...

Alexandria Venture Investments
VC Fund · Pasadena, California, United States · 107 investments in United States Biotechnology startups

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Canada, France

Investor stats

  • Total investments: 264
  • Round size: Seed $2M–$31M; Series A $12M–$101M; Series B $25M–$150M
  • Lead/follow: 8% lead, 92% follow

Portfolio highlights

  • miRecule — MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients. The company was founded in 2016 and headquartered in Gaithersburg, United States.
  • Deep Genomics — Revolutions in AI, biology and automation are enabling a new approach to medicine. Deep Genomics is at the forefront.
  • Vedana Therapeutics — Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
Show all investments...

OrbiMed
VC Fund · New York, New York, United States · 88 investments in United States Biotechnology startups

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, China, Israel

Investor stats

  • Total investments: 615
  • Round size: Series A $10M–$140M; Series B $24M–$151M; Series C $15M–$131M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Avedro — Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross-linking. Avedro recently completed its US‐based, multi-centered, Phase III studies of corneal cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Outside the UnitedStates, Avedro has commercialized both VibeX and its KXL System for performing Lasik Xtra and accelerated cross-linking. Additionally, Avedro is developing the science of Thermo‐biomechanics for therapeutic medical applications. The Keraflex® refractive correction procedure is the first technology developed from the Thermo‐biomechanics platform and is a non‐invasive, incision‐less ophthalmic procedure for flattening the cornea without the removal of tissue. Keraflex offers the unique ability to induce refractive change without weakening the cornea’s biomechanical integrity, as happens with Lasik and other refractive correction procedures. Keraflex is commercially available outside of the United States.
  • Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
  • EDDA Technology — EDDA Technology offers computer assistance to the patient care management cycle and enables early detection and diagnosis of diseases.
Show all investments...

Atlas Venture
VC Fund · Cambridge, Massachusetts, United States · 78 investments in United States Biotechnology startups

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 432
  • Round size: Series A $3.5M–$75M; Series B $8M–$115M; Series C $6M–$95M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Grockit — Grockit is a pioneering online social learning company. Grockit has proven that people learn more, faster through combining social learning mechanics and multi-media learning content to help people teach and learn from others. Grockit.com offers Test Prep services for GMAT, IIM CAT, LSAT, GRE, ACT, SAT and AP Calculus and AP History tests.Grockit has built a social learning test prep platform for license and direct-to-consumer products. Florida Virtual Schools, KIPP Schools, Georgetown University and other schools have deployed Grockit services.
  • Songbird — DropCatch.com helps you secure expiring domain names.
  • Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
Show all investments...

New Enterprise Associates
VC Fund · Menlo Park, California, United States · 71 investments in United States Biotechnology startups

Foundational partners to ambitious founders at every stage of company-building.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Series B, Series C
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1581
  • Round size: Series A $5.4M–$60M; Series B $10M–$77M; Series C $14M–$103M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely still investing — raised $2.8B in 2022

Portfolio highlights

  • IonQ — Working to build the world's best quantum computers to solve the world's most complex problems
  • Spyglass Ophthalmics — A vision towards a higher quality of life!
  • Xenon Pharmaceuticals — A leading neuroscience company forging new paths for those living with neurological and psychiatric disorders.
Show all investments...

Versant Ventures
VC Fund · Menlo Park, California, United States · 70 investments in United States Biotechnology startups

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, Canada

Investor stats

  • Total investments: 287
  • Round size: Series A $4.7M–$84M; Series B $10M–$105M; Series C $12M–$108M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Graphite Bio — Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases
  • Lycia Therapeutics — Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.
  • Nested Therapeutics — Nested Therapeutics is a Cambridge-based VC-backed stealth biotech company. The company's focus is on finding and creating new precision oncology small-molecule drugs targeted toward cancer genes. Nested Therapeutics was established in 2021 in Cambridge, Massachusetts.
Show all investments...

Alumni Ventures
VC Fund · Manchester, New Hampshire, United States · 69 investments in United States Biotechnology startups

Access curated startup investment opportunities and diversified venture capital exposure designed for accredited investors.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Seed, Series A, Series B
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 1791
  • Round size: Seed $1.5M–$10M; Series A $5.5M–$37M; Series B $11M–$79M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • NextDroid — NextDroid - We're Doing Something Different
  • Enact — Enact is a leading solar energy and solar software company serving homeowners, businesses, and installers. Get a free quote or request a demo today!
  • ARRIS — Using next-gen advanced manufacturing technologies, ARRIS Composites produces smarter, lighter, stronger, and more sustainable products at scale.
Show all investments...

Third Rock Ventures
VC Fund · Boston, Massachusetts, United States · 67 investments in United States Biotechnology startups

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States

Investor stats

  • Total investments: 163
  • Round size: Series A $19M–$110M; Series B $11M–$190M; Series C $14M–$108M
  • Lead/follow: 45% lead, 55% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Corvia Medical — Corvia Medical is a medical device company, focuses on developing structural heart devices for the treatment of heart failure. The company develops InterAtrial Shunt Device (IASD), a transcatheter device designed to treat diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF). It was founded in 2009and headquartered in Andover, Massachusetts.
  • Jounce Therapeutics — Concentra is a biosciences company.
  • Terremoto Biosciences — By unleashing the power of covalent chemistry, we can deliver superior small molecule medicines with enhanced therapeutic benefit.
Show all investments...

Khosla Ventures
VC Fund · Menlo Park, California, United States · 64 investments in United States Biotechnology startups

Khosla Ventures is a venture capital firm that invests in early- to late-stage companies across sectors like AI, healthcare, sustainability, and consumer technology. It manages multiple funds, focusing on startups with innovative technologies or business models. The firm primarily targets sectors like AI, climate tech, digital health, and medtech,offering strategic support to help build long-lasting companies.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Health Care
  • Stage:Series A, Series B, Seed
  • Geography: United States, India, United Kingdom

Investor stats

  • Total investments: 1160
  • Round size: Seed $2M–$25M; Series A $5.5M–$47M; Series B $10M–$100M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely still investing — raised $557M in 2022

Portfolio highlights

  • Wattpad — Wattpad is a digital entertainment company providing an online social storytelling platform for original stories.The company utilizes the power of community and technology to enable the creation and distribution of content across a variety of formats. Its flagship app, Wattpad, is home to a community of more than 65 million people who spend over20 billion minutes a month engaged in original stories. Tap by Wattpad, the company’s second storytelling product, offers short, chat-based stories in over a dozen languages. Wattpad Studios co-produces stories for film, television, digital, and print, together with industry partners. Wattpad Brand Solutions offers a full suite of advertising products to help brands build deep engagement with Millennial and Gen Z consumers.It was established by Allen Lau and Ivan Yuen in Toronto, Ontario, Canada in 2006.
  • Breeze — Cargo insurance reinvented.
  • Shoes of Prey — Shoes of Prey creates bespoke, hand-made women's shoes designed by the customer, and delivers them to anywhere in the world.Shoes of Prey has grown rapidly over 5 years and has won a number of awards including Online Retailer of the Year and Store Design of the Year at the World Retail Awards in Paris 2013.Founded in 2009, the company isheadquartered in Santa Monica, California, United States.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Polaris Partners
VC Fund · Boston, Massachusetts, United States · 64 investments in United States Biotechnology startups

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, Ireland, Singapore

Investor stats

  • Total investments: 461
  • Round size: Series A $4.5M–$83M; Series B $7M–$107M; Series C $10M–$100M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $182M in 1998

Portfolio highlights

  • Living Proof — Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely newmolecules and breakthrough technologies for results you can see from across the room.
  • ReadyForZero — ReadyForZero creates online financial software that helps people tackle any debt and protect their credit - automatically. It's not a "debt negotiation" or "debt settlement" service. The company was co-founded by Rod Ebrahimi and Ignacio Thayer as part of Y Combinator in the Summer of 2010. ReadyForZero is aventure-backed technical product team based in San Francisco.
  • Seamless Receipts — Extensive selection of high-quality domain names. Knowledgeable, friendly customer support.
Show all investments...

RA Capital Management
VC Fund · Boston, Massachusetts, United States · 64 investments in United States Biotechnology startups

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series C, Post-IPO Equity
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 480
  • Round size: Series B $26M–$152M; Series C $44M–$183M; Post-IPO Equity $35M–$240M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
  • Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
  • Kinaset Therapeutics — Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts.
Show all investments...

5AM Ventures
VC Fund · Menlo Park, California, United States · 64 investments in United States Biotechnology startups

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 183
  • Round size: Series A $13M–$70M; Series B $16M–$110M; Series C $14M–$120M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely still investing — raised $450M in 2022

Portfolio highlights

  • Skye Bioscience — Skye Bioscience is a pharmaceutical company providing new therapeutic outcomes for diseases with significant prevalence and unmet needs. It develops proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions.
  • Enliven Therapeutics — Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectivelydevelop precision oncology therapeutics that enhance overall patient well-being.Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado.
  • Magnetic Insight — Magnetic Insight (MI) introduced magnetic particle imaging into the preclinical diagnostic research market enabling quantitative cell tracking, imaging of vascular function, detecting metastatic tumors, visualizing inflammation, CAR-T cell therapies and initial research into regenerative medicine.
Show all investments...

Innova Memphis
VC Fund · Memphis, Tennessee, United States · 63 investments in United States Biotechnology startups

Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.

Show more...

Investment focus

  • Industry: Health Care, Medical, Medical Device
  • Stage:Seed, Pre-Seed
  • Geography: United States, Argentina, United Kingdom

Investor stats

  • Total investments: 252
  • Round size: Seed $50k–$1.7M; Pre-Seed $25k–$1.3M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
  • Insignum AgTech — Insignum AgTech develops biotech plants that communicate with producers, alerting them to an illness in its early stages.
  • Rescue Forensics — Customer service is our #1 priority. Get a premium domain for your website today. Financing available.
Show all investments...

MPM Capital
VC Fund · Cambridge, Massachusetts, United States · 61 investments in United States Biotechnology startups

Powering Breakthroughs in Life Sciences

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A, Series C
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 227
  • Round size: Series A $9M–$84M; Series B $20M–$125M; Series C $12M–$100M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely still investing — raised $850M in 2021

Portfolio highlights

  • Orna Therapeutics — Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
  • Aratana Therapeutics — Aratana is uniquely positioned to deliver new, high-quality medicines to address unmet needs in companion animal care. We are committed to bringing world class science to animal health for companion animals and the people who care for them. Our competitive advantage resides in our ability to identify, acquire and develop high-value commercialproducts for companion animals in a cost effective and efficient manner.
  • Rhythm Pharmaceuticals — Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Show all investments...

F-Prime
VC Fund · Cambridge, Massachusetts, United States · 60 investments in United States Biotechnology startups

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, China

Investor stats

  • Total investments: 434
  • Round size: Series A $9.2M–$87M; Series B $15M–$112M; Series C $22M–$165M
  • Lead/follow: 26% lead, 74% follow

Portfolio highlights

  • Vestwell — Vestwell is a digital savings platform redefining the way workplace plans are powered today.
  • Lemon Cash — Lemon Cash is digital wallet with FIAT and crypto capabilities. End to end digital ecosystem for Latin America.
  • Checkmate Pharmaceuticals — Empowering the immune system to beat back cancer
Show all investments...

Gaingels
VC Fund · New York, New York, United States · 59 investments in United States Biotechnology startups

Gaingels is a venture investment syndicate in service of the LGBT+ community and its allies, investing in companies with LGBT+ founders and C-suite leaders at all stages of growth, as well as in more established companies resolved on building more inclusive teams, with a global portfolio of 130+ companies and $70M in deployed investment capital todate. The Gaingels network also actively supports its portfolio in identifying and recruiting diverse talent to their C-suite and board leadership teams and fosters a vibrant global community of industry leaders, investors, operators, and entrepreneurs who share a common goal for positive social change through business and successful investments.

Show more...

Investment focus

  • Industry: Software, Health Care, Artificial Intelligence
  • Stage:Seed, Series A, Series B
  • Geography: United States, Canada, Mexico

Investor stats

  • Total investments: 1006
  • Round size: Seed $1.1M–$8.1M; Series A $5M–$40M; Series B $16M–$100M
  • Lead/follow: 1% lead, 99% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • BQP — BosonQ Psi Pvt. Ltd. (BQP) is a state-of-the-art SaaS-based enterprise software venture leveraging the power of Quantum computing to speed up virtual simulations of Multiphysics and Computer-Aided Engineering (CAE) nature. BosonQ Psi is at the forefront of this quantum revolution. Our vision is to become the premier multiphysics simulation softwareusing quantum computing. Our world-class software suite will include computational science fields of fluid dynamics, structural dynamics, thermal, chemical, and aeroacoustics. With such an innovative product, we will revolutionize the computational world by enabling high-fidelity simulations that are impossible to solve with current computing technology. Further, this product will aid aerospace, automotive, energy, manufacturing, biotechnology, civil engineering, and astrophysics industries in saving millions of dollars by reducing long turnaround times of simulations used in the design process and give higher accuracy to make significant design changes for giving rise to the next generation of an electric car, eVTOL, skyscraper, or even Mars Rover.The possibility to harness the power of quantum computers is endless, and we at BQP thrive on pushing the boundaries of quantum computing technologies to serve our clients. We have made it our mission to bring these possibilities into the hands of every person - from a researcher to a scientist, from a professor to a student. Our name, BosonQ Psi, pays tribute to the great Indian physicist Dr. Satyendra Nath Bose, after whose name the elementary particle in quantum mechanics, Boson, was named and further incorporates the fundamental quantity that describes the state of the quantum particle - Psi, thus symbolizing the company's fundamental goal to contribute in India's goal to be the leader in the Quantum realm and also become a global leader in Quantum paradigm shift in coming years.
  • Willow Wealth — Willow Wealth is an alternative investment platform focused on generating income streams for investors. Get exclusive access to private market investments.
  • Hubble Network — Connect a Bluetooth device to a global satellite network, delivering affordable, low-power tracking and monitoring for diverse industrial and commercial applications.
Show all investments...

Google Ventures
VC Fund · Mountain View, California, United States · 58 investments in United States Biotechnology startups

GV supports innovative founders moving the world forward.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Israel

Investor stats

  • Total investments: 1113
  • Round size: Seed $1.1M–$16M; Series A $6M–$100M; Series B $15M–$121M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $100M in 2014

Portfolio highlights

  • Smarterer — Individuals and Fortune 500 companies use Smarterer to help close the gap between the skills they have and the skills they need. Their dynamic assessment engine leverages the freshest crowdsourced tests around, to rapidly pinpoint skill level with a credible score. In November 2014, Pluralsight, the global leader in online learning for serioussoftware developers, IT specialists and creative technologists, acquired Smarterer. As the world's largest curated e-learning library for professionals, the company offers instant access to more than 3,500 courses authored by top experts. Smarterer will continue to power crowdsourced assessments for freelancer marketplaces, e-learning providers and enterprise companies anywhere people need to prove their skills to connect with professional opportunities. The Smarterer community has answered over 56 million during 1.7 million test sessions, across hundreds of tests.
  • Cord Project — Cord is incredibly simple, incredibly fast voice messaging that lets you chat with one friend or shout to a whole group of friends. Start chatting for free on iPhone or Android now.
  • Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
Show all investments...

Canaan Partners
VC Fund · Menlo Park, California, United States · 52 investments in United States Biotechnology startups

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Israel

Investor stats

  • Total investments: 673
  • Round size: Series A $5M–$42M; Series B $8M–$75M; Series C $7.1M–$55M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: Likely still investing — raised $100M in 2024

Portfolio highlights

  • withco — withco is a provider of real estate and technology services for small businesses. withco was founded in 2019 and is based in Brooklyn, NY, USA.
  • Berkshire Grey — Berkshire Grey develops a materials handling system intended to automate omnichannel fulfillment. Its system utilizes artificial intelligence, computer vision, machine learning, and novel sensing to deploy intelligent robotic systems that automate tasks never before performed by machines in commercial settings, enabling customers to achieve higheraccuracy and throughput speeds than traditional approaches as well as handle the broadest assortment of products, packaging, and parcels with ease.
  • GroundWork — GroundWork delivers Unified Monitoring for Real™ with an open software platform for shockingly easy integrations and customized visualizations of cloud, virtualization, network, application, server, and storage data.GroundWork Monitor is available in free (Core) and subscription versions with support (Enterprise).GroundWork was founded in 2004 andis headquartered in San Francisco, California with partners in Asia Pacific, Europe and South America.
Show all investments...

Andreessen Horowitz
VC Fund · Menlo Park, California, United States · 51 investments in United States Biotechnology startups

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Brazil

Investor stats

  • Total investments: 1771
  • Round size: Seed $1.6M–$20M; Series A $9M–$55M; Series B $16M–$112M
  • Lead/follow: 49% lead, 51% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Cazena — Cloudera delivers a hybrid data platform with secure data management and portable cloud-native data analytics.
  • Shapeways — Shapeways is the #1 online 3D printing service company. Working with over a million customers since 2007 - Get 3D products and parts delivered to over 100 countries.
  • Co:Create — The Co:Create protocol provides the foundational infrastructure for decentralized brands of the future. It enables projects to mint NFTs, as well as launch their own DAOs and fungible tokens associated with their collections.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
BioAdvance
VC Fund · Philadelphia, Pennsylvania, United States · 48 investments in United States Biotechnology startups

BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United States, Canada

Investor stats

  • Total investments: 120
  • Round size: Seed $350k–$3M; Series A $3M–$40M
  • Lead/follow: 13% lead, 87% follow
  • Last fund: May invest from a new fund soon — raised $20M in 2002

Portfolio highlights

  • Latus Bio — Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing.
  • Overwatch Health — Overwatch Health offers an AI-assisted virtual rehab for cardiac and pulmonary patients.
  • Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Show all investments...

The Column Group
VC Fund · San Francisco, California, United States · 46 investments in United States Biotechnology startups

The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States

Investor stats

  • Total investments: 141
  • Round size: Series A $9.2M–$102M; Series B $22M–$115M; Series C $33M–$107M
  • Lead/follow: 37% lead, 63% follow

Portfolio highlights

  • Peloton Therapeutics — Peloton Therapeutics is translating groundbreaking scientific insights into first-in-class oral medicines to fight cancer and other serious conditions.
  • NGM Biopharmaceuticals — Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
  • Constellation Pharmaceuticals — Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression.
Show all investments...

KdT Ventures
VC Fund · Austin, Texas, United States · 46 investments in United States Biotechnology startups

KdT Ventures is the standard for early-stage frontier science investing.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United States, India, Canada

Investor stats

  • Total investments: 93
  • Round size: Seed $2.6M–$13M; Series A $8.5M–$70M; Series B $25M–$175M
  • Lead/follow: 9% lead, 91% follow
  • Last fund: Likely still investing — raised $80M in 2022

Portfolio highlights

  • Zag Bio — Zag Bio is harnessing the immune system in a whole new way by targeting the thymus to change treatment possibilities for millions of patients with autoimmune diseases.
  • Skeletalis — Skeletalis is a biotechnology startup focused on developing next-generation precision medicines for musculoskeletal diseases, primarily osteoporosis.
  • Tacit Therapeutics — Tacit Therapeutics created RNA-targeting treatments for devastating diseases. By repurposing pre-existing components of human cells, we have created the first broadly applicable and inherently non-immunogenic means to repair mutated genes. The company was founded in 2021 and is based in South San Francisco, California.
Show all investments...

Connecticut Innovations
VC Fund · Rocky Hill, Connecticut, United States · 45 investments in United States Biotechnology startups

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Seed, Series A
  • Geography: United States, Israel, Canada

Investor stats

  • Total investments: 259
  • Round size: Seed $300k–$5.3M; Series A $2.4M–$25M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: Likely still investing — raised $50M in 2023

Portfolio highlights

  • 1touch.io — By continuously analyzing traffic and repository stores connected to your network, our network-based solution can detect all elements on the network that are storing, processing, and sharing personal data, both internally and externally. Whether structured or unstructured data, data in motion or at rest, and even data that is unknown to you,1touch.io can track it for you.
  • Mobile Sense — The traditional diagnostic market is being transformed by advances in high performance wearables. This seismic shift led by consumer products which are uncovering new patients who previously went undetected, but still require a detailed diagnosis. Mobile Sense™ is building foundational technology that enables this transformation throughoff-the-chest wearables for long term management of cardiac arrhythmias. Developed over 7 years with $4.2M in grant funding and $1.3M in seed funding, Mobile Sense™ has a platform for differentiated wearables. Our embedded algorithms coupled with non-adhesive, wireless & waterproof sensors provides high fidelity continuous ECG and PPG recordings. The automatic monitoring provides 24/7, 365 days/yr continuous detection and classification of dangerous heart arrhythmias.
  • LegiTime Technologies — Miami Embracing New Technology and Safety
Show all investments...

Lux Capital
VC Fund · New York, New York, United States · 45 investments in United States Biotechnology startups

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Health Care
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 556
  • Round size: Seed $1.8M–$30M; Series A $7.3M–$96M; Series B $13M–$193M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $100M in 2007

Portfolio highlights

  • Adimab — Premier Human Antibody Discovery and Optimization
  • Kyruus Health — Kyruus Health is a care access platform that provides solutions for providers data management, patient engagement, and activation.
  • Cajal Neuroscience — Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Show all investments...

Novartis Venture Fund
VC Fund · Basel, Basel-Stadt, Switzerland · 43 investments in United States Biotechnology startups

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 217
  • Round size: Series A $5.1M–$81M; Series B $11M–$120M; Series C $9M–$75M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — raised $200M in 2009

Portfolio highlights

  • Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
  • Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
  • Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
Show all investments...

Mission BioCapital
VC Fund · Cambridge, Massachusetts, United States · 43 investments in United States Biotechnology startups, 8 in the past 12 months

Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B
  • Geography: United States, Switzerland, France

Investor stats

  • Total investments: 94
  • Round size: Series A $4.2M–$80M; Series B $21M–$112M
  • Lead/follow: 22% lead, 78% follow
  • Last fund: Likely still investing — raised $275M in 2021

Portfolio highlights

  • Deck Bio — Deck Bio develops multi-target T cell engager immunotherapies for solid tumors.
  • Beech Biotech — Beech Biotech is utilizing cutting-edge biology to develop innovative therapies for preeclampsia and other pregnancy-related issues. This business extends pregnancy and lessens the effects of premature birth.
  • Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
Show all investments...

DCVC
VC Fund · San Francisco, California, United States · 41 investments in United States Biotechnology startups

We are deep tech venture capital.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Machine Learning
  • Stage:Seed, Series A, Series B
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 392
  • Round size: Seed $1.5M–$10M; Series A $5.8M–$45M; Series B $15M–$130M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: Likely still investing — raised $1B in 2023

Portfolio highlights

  • Agility — Agility develops humanoid robots and automation platforms for warehouse, manufacturing, and logistics operations. It provides robotic deployment solutions and software platforms that support industrial automation and the handling of repetitive tasks. The company also offers software platforms to manage and support robotic operations in industrialenvironments.
  • CH4 Global — CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change at scale. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced bycows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in Henderson, NV.
  • Tradeshift — Tradeshift is a supply chain network, Tradeshift is a market leader in e-invoicing and accounts payable automation and an innovator in supplier financing and B2B marketplaces.
Show all investments...

Fifty Years
VC Fund · San Francisco, California, United States · 41 investments in United States Biotechnology startups

WE BACK HEROES using technology to solve the world's biggest problems

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Artificial Intelligence
  • Stage:Seed, Series A, Series B
  • Geography: United States, Germany, Canada

Investor stats

  • Total investments: 163
  • Round size: Seed $2M–$15M; Series A $8.5M–$40M; Series B $16M–$91M
  • Lead/follow: 18% lead, 82% follow
  • Last fund: Likely still investing — raised $90M in 2021

Portfolio highlights

  • Onepot.ai — Onepot.ai offers automated synthesis of small molecules from basic building blocks using a unified, end-to-end process. It generates around fifty distinct compounds in a single workflow, eliminating the need for bespoke methods for each target. The platform employs modular couplings, deprotection, and streamlined purification steps to rapidlyassemble structurally diverse molecules. It supports chemistries that produce both sp²- and sp³-rich frameworks, enabling applications across pharmaceutical, materials, and probe development. By leveraging a catch-and-release purification protocol and iterative building-block assembly, Onepot.ai enables efficient production of complex small-molecule libraries.
  • Adaption Labs — Adaptation creates AI systems that adjust to changing real-world circumstances.
  • Tools For Humanity — Tools for Humanity is a technology company building for humans in the age of AI.
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 40 investments in United States Biotechnology startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 351
  • Round size: Series A $9M–$125M; Series B $13M–$135M; Series C $30M–$118M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
  • IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Dolby Family Ventures
VC Fund · San Francisco, California, United States · 40 investments in United States Biotechnology startups, 7 in the past 12 months

Investing in early-stage companies solving the biggest science and engineering challenges since 2014.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: United States, Austria, Germany

Investor stats

  • Total investments: 143
  • Round size: Seed $2M–$9.4M; Series A $6.5M–$50M; Series B $10M–$75M
  • Lead/follow: 8% lead, 92% follow

Portfolio highlights

  • Exciva — EXCIVA GmbH is a privately held biotech company focused on development of clinical stage therapeutics for various indications in neuropsychiatry.
  • Transition Metal Solutions — Transition Biomining is a metal ore mining technology company that offers data driven solutions for copper extraction and mining.
  • MindImmune Therapeutics — Breaking through barriers to new therapeutics for brain disease.
Show all investments...

Pfizer Venture Investments
VC Fund · New York, New York, United States · 39 investments in United States Biotechnology startups

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 173
  • Round size: Series A $10M–$100M; Series B $20M–$123M; Series C $15M–$102M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — raised $600M in 2018

Portfolio highlights

  • VitaDAO — Join VitaDAO, a community owned collective funding early stage longevity research. We fund and commercialize longevity therapeutics.
  • Ixchelsis — Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose studyin healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.
  • Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
Show all investments...

Hatteras Venture Partners
VC Fund · Durham, North Carolina, United States · 39 investments in United States Biotechnology startups

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Canada

Investor stats

  • Total investments: 131
  • Round size: Series A $5.2M–$50M; Series B $5M–$90M; Series C $8M–$88M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Ribometrix — The Next Frontier of Drug Discovery
  • G1 Therapeutics — G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigationaltherapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.
  • Viamet Pharmaceuticals — Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allowsthem to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.
Show all investments...

Sofinnova Investments
VC Fund · Menlo Park, California, United States · 38 investments in United States Biotechnology startups

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A, Series C
  • Geography: United States, France, Switzerland

Investor stats

  • Total investments: 217
  • Round size: Series A $7.3M–$115M; Series B $15M–$150M; Series C $15M–$94M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $650M in 2016

Portfolio highlights

  • NextCure — NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
  • Spark Therapeutics — Breakthrough science. One moment, one day, one person at a time.
  • Marinus Pharmaceuticals — Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.
Show all investments...

Frazier Healthcare Partners
VC Fund · Seattle, Washington, United States · 38 investments in United States Biotechnology startups

With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Post-IPO Equity
  • Geography: United States, Canada, Ireland

Investor stats

  • Total investments: 173
  • Round size: Series A $10M–$73M; Series B $10M–$110M; Post-IPO Equity $15M–$235M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: Likely still investing — raised $987M in 2022

Portfolio highlights

  • Simpata — Simpata Inc is a software company that provides its clients with internet-based application services of employee human resources.
  • Zeltiq Aesthetics — Learn about the CoolSculpting cryolipolysis procedure.
  • Radionetics Oncology — Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics.
Show all investments...

Northpond Ventures
VC Fund · Bethesda, Maryland, United States · 38 investments in United States Biotechnology startups

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Life Science
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 137
  • Round size: Series A $13M–$68M; Series B $10M–$100M; Series C $22M–$85M
  • Lead/follow: 60% lead, 40% follow

Portfolio highlights

  • Vizgen — Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The highthroughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
  • Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
  • EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
Show all investments...

Civilization Ventures
VC Fund · San Francisco, California, United States · 37 investments in United States Biotechnology startups

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United States, United Kingdom, Brazil

Investor stats

  • Total investments: 73
  • Round size: Seed $1.7M–$16M; Series A $8.1M–$30M; Series B $24M–$144M
  • Lead/follow: 3% lead, 97% follow

Portfolio highlights

  • OxCan — Enabling curative cancer treatment through early detection
  • 10x Science — 10x Science offers an AI software that analyzes protein data to characterize molecular structures and support biopharmaceutical research.
  • Foresight Diagnostics — We develop innovative diagnostics to advance decision-making in oncology drug development and patient care.
Show all investments...

Boston Harbor Angels
VC Fund · Boston, Massachusetts, United States · 36 investments in United States Biotechnology startups

Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical Device
  • Stage:Angel, Seed, Series A
  • Geography: United States, Canada, India

Investor stats

  • Total investments: 107
  • Round size: Seed $100k–$2.9M; Angel $500k–$1.6M; Series A $662k–$6M
  • Lead/follow: 8% lead, 92% follow

Portfolio highlights

  • Gelmedix — Gelmedix is a developer of a biomaterial platform to improve drug delivery for complicated ophthalmic treatment. The company's platform offers a single non-invasive gel patch that can be used as a drug-eluting sealant with tissue adhesion, tunable drug elution, and biocompatibility properties, thereby enabling healthcare providers to reducethe usage of drops which cause inconvenience to patients.
  • Zylö Therapeutics — Patented technology that enables, for topicals, sustained release, increased druggability, a Patchless Patch concept, and enhanced targeting of pores and follicles
  • Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Show all investments...

Apple Tree Partners
VC Fund · New York, New York, United States · 36 investments in United States Biotechnology startups

ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 81
  • Round size: Seed $3.8M–$8M; Series A $20M–$75M; Series B $9.3M–$90M
  • Lead/follow: 62% lead, 38% follow
  • Last fund: May invest from a new fund soon — raised $1B in 2020

Portfolio highlights

  • Adendra Therapeutics — Adendra is an emerging biotechnology company building on new insights into dendritic cell biology to discover and develop new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases.
  • Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
  • Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.
Show all investments...

Omega Funds
VC Fund · Boston, Massachusetts, United States · 36 investments in United States Biotechnology startups

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 154
  • Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Attenua — 100% satisfaction guaranteed. Hassle-free shopping. We help you find the right domain name.
  • Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
  • Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Refactor
VC Fund · Burlingame, California, United States · 36 investments in United States Biotechnology startups

Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United States, United Kingdom, New Zealand

Investor stats

  • Total investments: 106
  • Round size: Seed $2.7M–$9M; Series A $10M–$34M; Series B $16M–$103M
  • Lead/follow: 19% lead, 81% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Pila Energy — Pila Energy develops innovative battery systems and software to provide energy security and energy management for homes and businesses. The company offers a plug-and-play battery solution for renters and homeowners alike that installs via standard outlets, providing backup power, energy savings, and intelligent load management without complexinstallation overhead. Pila’s system integrates advanced battery storage, power electronics, and mesh networking software to optimize energy use and enhance resilience. Pila Energy was founded in 2024 and is headquartered in San Francisco, CA.
  • The Biological Computing — Biological Black Box integrates biological neurons with artificial neural networks to develop a living computer.
  • Berkeley Yeast — Better yeast for better beer. Make cleaner tasting beer with ultra low diacetyl strains, brew non alcoholic beer that tastes more like actual beer, or unlock bright grapefruit and passionfruit notes with the cleanest thiol yeast.
Show all investments...

Illumina Ventures
VC Fund · Foster City, California, United States · 35 investments in United States Biotechnology startups, 14 in the past 12 months

We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, United Kingdom, France

Investor stats

  • Total investments: 88
  • Round size: Series A $8M–$60M; Series B $10M–$220M; Series C $22M–$112M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • CubaseBio — Cubase Bio is a biotechnology business that focuses on spatial biology tools. It creates solutions for 3D spatial analysis to speed up drug discovery.
  • SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
  • Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Show all investments...

Life Science Angels
VC Fund · Sunnyvale, California, United States · 35 investments in United States Biotechnology startups

Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United States, Israel, The Netherlands

Investor stats

  • Total investments: 88
  • Round size: Seed $1M–$4M; Series A $1.3M–$20M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • ATDev — ATDev provides assistive technology and medical device solutions.
  • Journey Live — Journey is shifting the way modern companies prioritize mental health. Our proactive, inclusive tools engage every employee, every day.
  • Trio Pharmaceuticals — Trio Pharmaceuticals is a cancer therapeutics company that develops dual-action drugs for immunogenic tumors. These drugs directly stop tumor growth and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. The company was founded in 2018 and is headquartered in San Diego, California.
Show all investments...

Founders Fund
VC Fund · San Francisco, California, United States · 35 investments in United States Biotechnology startups

Founders Fund is a San Francisco based venture capital firm investing in companies building revolutionary technologies.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Germany

Investor stats

  • Total investments: 821
  • Round size: Seed $1.5M–$16M; Series A $5.6M–$50M; Series B $15M–$100M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Quantcast — We are taking an entirely new approach to advertising on the open internet.
  • Workstream — Workstream is an automated hiring platform that helps companies employing hourly workers. The platform helped Jamba, Chick-fil-A, McDonald's, Dunkin', Applebee's, Auntie Anne's, Cinnabon to increase their bottom line and cost savings.Workstream was founded in 2017 and is headquartered in San Francisco, California, UnitedStates.
  • Valinor Enterprises — Valinor is a new kind of defense and government tech company. We build and buy mission-critical technologies to fill the gaps others ignore.
Show all investments...

General Catalyst
VC Fund · Cambridge, Massachusetts, United States · 34 investments in United States Biotechnology startups

Investing in powerful, positive change that endures

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Health Care
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, India

Investor stats

  • Total investments: 1851
  • Round size: Seed $1.8M–$20M; Series A $6.5M–$75M; Series B $12M–$130M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • L2 — L2 was founded in 2010 on the belief that a brand's digital competency is inextricably linked to shareholder value. L2 uses proprietary research and tools, combined with academic rigor and progressive design, to provide managers with visibility into a brand's digital performance. L2 is tracking over 5,000 global brands and works withthe prestige and consumer sectors' largest and most iconic enterprises and brands.
  • Envoy Global — Envoy Global is committed to delivering a better way for companies to manage global immigration.
  • Manas AI — Manas AI uses proprietary AI, generative computational chemistry, and best-in-class biology to reduce the time and expense of traditional medicinal development while also revolutionizing cancer and rare illness treatments.
Show all investments...

Amgen Ventures
VC Fund · San Francisco, California, United States · 34 investments in United States Biotechnology startups

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 114
  • Round size: Series A $4.4M–$53M; Series B $11M–$110M; Series C $19M–$80M
  • Lead/follow: 12% lead, 88% follow
  • Last fund: May invest from a new fund soon — raised $100M in 2012

Portfolio highlights

  • EnClear Therapies — EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).
  • Ember LifeSciences — Ember LifeSciences spun out of Ember Technologies providing secure and sustainable cold chain solutions to serve healthcare industry.
  • Mindset Medical — Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona.
Show all investments...

Flagship Pioneering
VC Fund · Cambridge, Massachusetts, United States · 34 investments in United States Biotechnology startups

We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 210
  • Round size: Series A $5.5M–$75M; Series B $11M–$140M; Series C $12M–$123M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: Likely still investing — fund raised in 2024

Portfolio highlights

  • Montai Therapeutics — Harnessing untapped diverse chemistry with AI-enabled drug discovery to develop breakthrough small molecule medicines for chronic disease.
  • Foghorn Therapeutics — Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter whatour DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
  • Serif Bio­med­i­cines — Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies.
Show all investments...

Digitalis Ventures
VC Fund · New York, New York, United States · 33 investments in United States Biotechnology startups

Engineering solutions to complex problems in health through venture investment and company creation.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, China

Investor stats

  • Total investments: 106
  • Round size: Seed $1.5M–$16M; Series A $7.5M–$66M; Series B $13M–$132M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Somatix — A fully comprehensive monitoring solution with unique smartband technology. Solutions for SNFs, senior living, healthcare systems, and smoking cessation.
  • Girihlet — Girihlet is a provider of rapid and accurate deep sequencing services with a unique focus on developing novel technologies. Girihlet currently specializes in inexpensively sequencing and analyzing mtDNA and T cell receptors using novel, bias-free methods in order to harness their power as biomarkers for diagnostics in a variety of disorders.
  • Omni — Omni provides Healthy Vegan Dog Food in the UK, made by vets to be a nutritionally complete meal for your dog. Feed your dog all the goodness of plants backed by science.
Show all investments...

Domain Associates
VC Fund · San Diego, California, United States · 33 investments in United States Biotechnology startups

INVESTMENT ADVISORS TO THE FIRST VC FUND DEDICATED TO BIOTECH INVESTMENT MANAGER OF 9 SUBSEQUENT BIOTECH VC FUNDS

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, Canada, Estonia

Investor stats

  • Total investments: 194
  • Round size: Series A $3.8M–$50M; Series B $10M–$60M; Series C $10M–$57M
  • Lead/follow: 16% lead, 84% follow
  • Last fund: May invest from a new fund soon — raised $164M in 2016

Portfolio highlights

  • Bionano Genomics — Discover how Bionano is striving to elevate health and wellness for all through optical genome mapping (OGM) solutions that transform the way the world sees the genome.
  • Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
  • Fractyl Health — Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.
Show all investments...

8VC
VC Fund · San Francisco, California, United States · 32 investments in United States Biotechnology startups

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.

Show more...

Investment focus

  • Industry: Software, Health Care, Artificial Intelligence
  • Stage:Series A, Seed, Series B
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 525
  • Round size: Seed $2.5M–$13M; Series A $8M–$57M; Series B $17M–$175M
  • Lead/follow: 34% lead, 66% follow

Portfolio highlights

  • Karat — Karat helps companies hire top engineering talent by improving the quality, efficiency, and equity of their technical hiring process
  • Apex — Apex manufactures ESPA-class satellites, ranging from 40 to 400kg. Our first spacecraft bus platform, Aries, is built for LEO missions for earth observation, communications, and more. Configure the Aries bus to meet your specific mission profile.
  • Flywheel.io — Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from topuniversities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT.Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.
Show all investments...

Biotechnology VC funding in United States at a glance

Stats across 15k deals from 7.9k investors.

7.9k
investors
in United States Biotechnology startups
15k
deals
in United States Biotechnology startups
$13M
median round
in United States Biotechnology startups
44%
lead investors
lead at least one round
17%
Series A
most common funding stage

Access all 7871 VC funds in United States Biotechnology startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology VC Funds in United States investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 7871 VC funds investing in United States Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists